Neurocrine Biosciences (NBIX) Other Non-Current Assets (2010 - 2026)

Neurocrine Biosciences' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $73.6 million for Q1 2026.

• Quarterly Other Non-Current Assets rose 381.05% year-over-year to $73.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.6 million (up 381.05% YoY) and the FY2025 annual result came in at $59.5 million, up 14.42% from the prior year.
• Other Non-Current Assets was $73.6 million for Q1 2026 at Neurocrine Biosciences, up from $59.5 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $73.6 million in Q1 2026 and bottomed at $10.0 million in Q2 2022.
• A 5-year average of $36.6 million and a median of $35.9 million in 2023 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 468.18% — and 2025, when it tumbled 69.94%.
• Neurocrine Biosciences' Other Non-Current Assets stood at $25.0 million in 2022, then soared by 98.4% to $49.6 million in 2023, then increased by 4.84% to $52.0 million in 2024, then grew by 14.42% to $59.5 million in 2025, then rose by 23.7% to $73.6 million in 2026.
• Business Quant data shows NBIX's Other Non-Current Assets at $73.6 million in Q1 2026, $59.5 million in Q4 2025, and $20.3 million in Q3 2025.